Vesalius in the News...

 

VESALIUS CARDIOVASCULAR ANNOUNCES THE COMPLETION OF A SUCCESSFUL CHRONIC ANIMAL STUDY

PRESS RELEASE UPDATED: JAN 21, 2020

VANCOUVER, British Columbia, January 21, 2020 (Newswire.com)

Vesalius Cardiovascular Inc. (VCI), a pre-clinical stage medical device company developing novel percutaneous therapies for the treatment of mitral regurgitation, today announced the successful completion of their first 30-day chronic animal study using their mitral valve repair device. The predetermined endpoints of the study were the absence of device or valve thrombosis and the absence of leaflet injury due to the device, and both endpoints were robustly confirmed upon completion of the study.

“We are extremely pleased with the result of our first chronic study,” said Dr. Peter Skarsgard, veteran cardiac surgeon and VCI’s President, who performed the procedure with the help of Dr. Christopher Durkin, a cardiovascular anaesthesiologist, echocardiographer, and VCI’s Echocardiography Advisor. Echocardiographic images were obtained during the procedure, and subsequently at 7, 15, and 30 days, followed by a detailed ex-vivo examination of the heart and the implanted device. “This is the first chronic study with our leaflet remodelling device, and I can confirm the complete absence of thrombosis or any injury to the valve leaflets from contact between our remodelling device and the native leaflets. This is an extremely important milestone in the development of our solution,” added Dr. Skarsgard.

Prior to the chronic study, the VCI team performed 17 successful in-vivo acute experiments in 2019. “This positive result is a byproduct of the risk mitigation strategy in our development plan that VCI put in place at an early stage,” mentioned Vincent Ledoux, VCI’s Chief Operating Officer, adding that “30 days of data is extremely significant at this stage. In addition to the main endpoints, our other observations from this study will directly inform design decisions going forward, to ensure that our complete system which includes the device itself as well as the delivery system, is safe, effective, durable, and adoptable.”

Armed with seven biomedical engineers who receive daily clinical inputs from the company’s four specialized physician advisors, VCI aims to produce a surgically inspired implantable medical device that can repair degenerative mitral regurgitation, a very common and potentially fatal disease, without open heart surgery. The VCI device will be delivered through a catheter (transfemoral/transseptal) during a procedure that will require an overnight stay in hospital, followed by two days of patient recovery at home, a remarkable improvement in comparison to recovery from the gold standard treatment of open heart surgery. Their unique solution saves time, energy and money, and by significant risk reduction, permits the treatment of patients who cannot undergo an open heart surgery due to prohibitive risk.

“This milestone is a high point in a continuum of successes that we expect to achieve during the year, from both clinical and engineering sides, which will allow us to reach the First-In-Human study by end of 2021,” added Dr. Skarsgard.

 

Vesalius is selected to pitch at the 2019 Life Sciences British Columbia (LSBC) Investors Summit

November 6, 2019 - JW Marriott Parq Hotel, Vancouver

For the third year in a row, Vesalius is selected to pitch at the LSBC Investors Summit, a regional event held to connect investor stakeholders with the healthcare innovation industry through company pitches, meetings and networking. This event is presented By Lumira Ventures.

Once again, this summit gives Vesalius the opportunity to increase their investor connections in Vancouver and beyond, gaining more exposure while updating followers and supporters.

 

 

Vesalius team is attending TCT 2019 in San Francisco

September 25-29, 2019 - Moscone Convention Center, San Francisco

Vesalius team is attending TCT 2019 in San Francisco. This very specialized conference is the ideal occasion to learn more about the latest therapies in interventional cardiology and connect with corporations active in this field. 

 

Vesalius wins top prize of $300,000 at the 2019 VGH and UBC Hospital Foundation Innovators’ Challenge

May 9, 2019 - VGH and UBC Hospital Foundation Innovators’ Challenge, Vancouver

The VGH and UBC Hospital Foundation Innovators’ Challenge looks for three local medical teams involved in groundbreaking research and development to pitch their innovations to the Accelerator Panel. Vesalius was selected as one of three members of the health and technology industry, to pitch to a panel of judges comprised of health tech executives.

On May 9th, Vesalius President, Dr. Peter Skarsgard, presented the company and research project at the Innovators’ Challenge, winning top prize of $300,000.

 

Vesalius is recognized on the 2019 Ready to Rocket Life Science List

March 12, 2019 - Ready to Rocket, British Columbia (BC)

Ready to Rocket is a recognition program for BC’s tech sector, publishing the revenue growth leaders of tomorrow. Based on their analysis of Vesalius, they determined the company is one of “the top private companies that are best positioned to capitalize on the trends for growth” (Ready to Rocket, 2019). Ready to Rocket recognized the company's growth for the 2nd consecutive year. On March 12th, Ready to Rocket announced Vesalius as 1 of the 10 companies to be recognized on their 2019 Ready to Rocket Life Science List.

 

Vesalius is featured in the Life Sciences Bristish Columbia (LSBC) Annual Magazine 2019

February 20, 2019 - LSBC, Vancouver

As the premier marketing piece for the BC life science ecosystem, LifeSciences BC publishes an annual magazine that identifies the innovation, pace and significant accomplishments of the life sciences sector in the last year. The 2019 theme for the magazine is Transformative Medicine: Targeted Insights – Advancing Discoveries.

On February 20th, Vesalius was featured in the LSBC Annual Magazine 2019, on pages 32-33. The article touches on the history of Vesalius, focusing on the problem being tackled and the growth and development of the project over the last 3 years, increasing awareness about their research.

We would like to thank LSBC for featuring us in the LSBC Annual Magazine 2019 and recognizing the research and development of our technology to help people facing mitral regurgitation.

 

Vesalius is selected to pitch at the 2018 Life Sciences British Columbia (LSBC) Investors Summit

October 25, 2018 - Fairmont Pacific Rim, Vancouver

The LSBC Investors Summit is held to connect investor stakeholders with the healthcare innovation industry through company pitches and discussions. They chose Vesalius to pitch at the Investors Summit, giving Vesalius the opportunity to increase their investor connections in Vancouver and gain more exposure on their valuable research.

 

Vesalius Cardiovascular Closes $1M Seed Investment Round - Plans Series-A Financing by End of Year

Vancouver, BC, May 28, 2018--(entrepreneurship@UBC)--Vesalius Cardiovascular Inc.  has announced the closing of a $1 million seed financing round to accelerate the engineering of its mitral valve repair device called Calla TC3.

The Vesalius unique concept marries surgery and cardiology to deliver a percutaneous treatment for mitral valve prolapse (also known as degenerative mitral regurgitation), a serious and very common heart valve disease.

"We use proven surgical principles to design and build Calla TC3, an innovative device able to reproduce the effect of surgical valve repair. More importantly, our device is delivered during a transcatheter intervention, requiring a small skin puncture to the leg of the patient and subsequently eliminating the need for open heart surgery" stated Dr. Peter Skarsgard, Vesalius' President, co-founder, and inventor of the device. "This financing round will enable the Company to accelerate the engineering phase and reach animal testing by early 2019".

Vesalius is developing a surgical implant able to repair the mitral valve without heart surgery. While the gold standard treatment remains open heart surgery, a large number of patients cannot undergo surgery because of the associated risks. Therefore, there exists an unmet clinical need.

The Vesalius device will allow all patients to be treated, while eliminating the burden of open heart surgery.

"Imagine the patient checking into the hospital for treatment on a Friday, returning home on Saturday, and back to normal activities on Monday" noted Vincent Ledoux, COO and co-founder of Vesalius. "The Company will be able to achieve 2 major milestones in 2018 and prepare for a Series A round by end of year".

 

Vesalius is selected to pitch at the 2018 BCTECH Summit in Vancouver

May 15, 2018 - Vancouver Convention Centre West, Vancouver

The BCTECH Summit is the largest innovation event in Western Canada, increasing international exposure for companies and connecting them with potential investors. The selection committee of international investors from successful startups in various sectors selected Vesalius to pitch at the BCTECH Summit.

 

Vesalius has been preselected to pitch at the 2018 UBC Investors Day in Vancouver

May 8, 2018 - University of British Columbia (UBC) Robson Square, Vancouver

After HATCH’s prescreening for innovative companies, Vesalius is pitching at UBC Investors Day. This opportunity allows Vesalius to increase awareness about their research project and make connections with local investors.

 

Vesalius is selected to pitch at the 2018 Capital Investment Network in Victoria

April 16, 2018 - Victoria Golf Club, Victoria

Capital Investment Network is dedicated to support companies in their early stages of development by connecting them to potential investors. Vesalius is selected to pitch at the Capital Investment Network, an Angel capital forum. Through attending this event, Vesalius will showcase their work and connect with new investors on Vancouver Island.

 

Vesalius attends 2018 Redefining Early Stage Investments (RESI) conference in Toronto

April 10, 2018 - Life Science Nation: RESI, Toronto

RESI is an international conference, hosted by Life Science Nation, for life science companies in their early stages of development to help companies secure potential funding through discussions with investors. Vesalius attended the RESI conference, developing their international relations and increasing their global recognition.

 

Vesalius places 2nd in the “International Company” category at the 2018 PitchfestNW in Portland

April 6, 2018 - TechfestNW, Portland

TechfestNW annually hosts PitchfestNW, an international startup competition that recognizes the work of innovative companies. Vesalius was preselected to attend the event and pitch to global venture capitalists. On April 6th, the selection committee chose Vesalius as one of the top five startups to present to the entire conference and a panel of special judges, resulting in them placing 2nd in the “International Company” category at the competition.

 

Vesalius is recognized on the 2018 Life Science Emerging Rocket List

March 14, 2018 - Ready to Rocket, British Columbia (BC)

Ready to Rocket is a recognition program for BC’s tech sector, publishing the revenue growth leaders of tomorrow. Based on their analysis of Vesalius, they determined the company is in early stages of development, but are a strong candidate for potential investors, because of their likelihood for future breakthroughs. On March 14th, Ready to Rocket announced Vesalius as 1 of the 10 BC companies to be recognized on the 2018 Life Science Emerging Rocket List.

 

Vesalius is selected to pitch at the 2018 BDO VC Day

March 8, 2018 - Binder Dijker Otte (BDO) Canada, Vancouver

In 2018, BDO hosted the VC (Venture Capitalist) Pitch Day, a pitching event that connects tech startups with potential investors. Vesalius is one of the few selected companies to pitch at the event, helping them spread knowledge on their research and device.

Vesalius is featured in the BDO Vancouver VC Day video on Youtube.

Vesalius successful at Cascadia Venture Forum Summit in Seattle 

November 15, 2017 - Cambie Grove, Seattle.

Competing this time with the top finishers in each Regional Forum (BC, OR, and WA), Vesalius again finishes in first place at the Cascadia Venture Forum Summit in Seattle, from a field of 7 startup companies in the Seed category. Proof of Concept and Product Market Fit for the Vesalius mitral valve repair device convinced voters within the audience and panel.

We would like the thank Cascadia for this amazing opportunity. 

As a part of this success, Vesalius is invited to engage with Keiretsu Forum, an Angel Investor community, with Deal Screening in December, and a Seed Deal pitch in Portland, Tacoma, Bellevue, Seattle and Vancouver, all in February 2018.

 

Vesalius pitches to Lumira Capital and other VCs at Invest in BC

October 18, 2017 - Terminal City Club, Vancouver.

Dr. Skarsgard, President of Vesalius Cardiovascular and inventor of the Calla-TC3 device, describes to investors how the Vesalius product line can benefit patients and fulfill the unmet need for patients with MR. Dr. Skarsgard explains how Calla-TC3 can relieve the “pains” of current surgical treatment, and provide “gains” for patients, providers, hospitals, and health institutions. See the slide deck for this event, coming soon.

 

Vesalius successful at Cascadia Venture Forum Vancouver

October 12, 2017 - VentureLabs, Vancouver.

Vesalius Cardiovascular finishes in first place at the Vancouver Cascadia Venture Forum, from a field of 6 startup ventures in the Seed category, as voted by the audience of angels, VCs, entrepreneurs, and business mentors. Vesalius will now proceed to the Cascadia Summit Competition to be held in Seattle on November 15, 2017.

Vesalius Cardiovascular Inc., 2016